{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:18:48Z","timestamp":1790983128771,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"DOI":"10.1007\/s12328-026-02444-8","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T09:38:17Z","timestamp":1789378697000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A case of refractory immune checkpoint inhibitor-induced colitis successfully treated with mirikizumab"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6310-7791","authenticated-orcid":false,"given":"Yuntae","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Takei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shino","family":"Babaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Tsunoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Kanomata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyuki","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"2444_CR1","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S1470-2045(22)00197-8","volume":"23","author":"LA Diaz","year":"2022","unstructured":"Diaz LA, Shiu K-K, Kim T-W, et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 2022;23:659\u201370. https:\/\/doi.org\/10.1016\/S1470-2045(22)00197-8.","journal-title":"Lancet Oncol"},{"key":"2444_CR2","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/S1470-2045(23)00049-9","volume":"24","author":"TK Choueiri","year":"2023","unstructured":"Choueiri TK, Eto M, Motzer R, et al. Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study. Lancet Oncol. 2023;24:228\u201338. https:\/\/doi.org\/10.1016\/S1470-2045(23)00049-9.","journal-title":"Lancet Oncol"},{"key":"2444_CR3","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1606774.","journal-title":"N Engl J Med"},{"key":"2444_CR4","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382:810\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1910549.","journal-title":"N Engl J Med"},{"key":"2444_CR5","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378:1789\u2013801. https:\/\/doi.org\/10.1056\/NEJMoa1802357.","journal-title":"N Engl J Med"},{"key":"2444_CR6","doi-asserted-by":"publisher","first-page":"102536","DOI":"10.1016\/j.eclinm.2024.102536","volume":"70","author":"P Gougis","year":"2024","unstructured":"Gougis P, Jochum F, Abbar B, et al. Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade\u2014a worldwide perspective. EClinicalMedicine. 2024;70:102536. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102536.","journal-title":"EClinicalMedicine"},{"key":"2444_CR7","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/CJI.0000000000000383","volume":"44","author":"AN Tran","year":"2021","unstructured":"Tran AN, Wang M, Hundt M, et al. Immune checkpoint inhibitor-associated diarrhea and colitis: a systematic review and meta-analysis of observational studies. J Immunother. 2021;44:325\u201334. https:\/\/doi.org\/10.1097\/CJI.0000000000000383.","journal-title":"J Immunother"},{"key":"2444_CR8","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, Salem J-E, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors. JAMA Oncol. 2018;4:1721. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3923.","journal-title":"JAMA Oncol"},{"key":"2444_CR9","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ejca.2022.08.029","volume":"176","author":"TU Schulz","year":"2022","unstructured":"Schulz TU, Zierold S, Sachse MM, et al. Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: prevalence and impact on patients\u2019 health-related quality of life. Eur J Cancer. 2022;176:88\u201399. https:\/\/doi.org\/10.1016\/j.ejca.2022.08.029.","journal-title":"Eur J Cancer"},{"issue":"Supplement 1","key":"2444_CR10","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.3393\/ac.2020.00213.0030","volume":"37","author":"HJ Cho","year":"2021","unstructured":"Cho HJ, Kim WR, Kim J-H, et al. Colonic perforation after treatment with nivolumab in esophageal cancer: a case report. Ann Coloproctol. 2021;37(Supplement 1):S39\u201343. https:\/\/doi.org\/10.3393\/ac.2020.00213.0030.","journal-title":"Ann Coloproctol"},{"key":"2444_CR11","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1097\/MCG.0b013e31828f1d51","volume":"47","author":"KA Mitchell","year":"2013","unstructured":"Mitchell KA, Kluger H, Sznol M, et al. Ipilimumab-induced perforating colitis. J Clin Gastroenterol. 2013;47:781\u20135. https:\/\/doi.org\/10.1097\/MCG.0b013e31828f1d51.","journal-title":"J Clin Gastroenterol"},{"key":"2444_CR12","doi-asserted-by":"publisher","first-page":"413","DOI":"10.12788\/jhm.2925","volume":"13","author":"JA Marin-Acevedo","year":"2018","unstructured":"Marin-Acevedo JA, Harris DM, Burton MC. Immunotherapy\u2010induced colitis: an emerging problem for the hospitalist. J Hosp Med. 2018;13:413\u20138. https:\/\/doi.org\/10.12788\/jhm.2925.","journal-title":"J Hosp Med"},{"key":"2444_CR13","unstructured":"Schneider BJ, Brahmer J, McPherson J et al. Management of Immune Checkpoint Inhibitor-Related Toxicities, Version 1.2026. NCCN Clinical Practice Guidelines in Oncology; 2025. https:\/\/www.nccn.org\/"},{"key":"2444_CR14","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen J, Obeid M, Spain L, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:1217\u201338. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.001.","journal-title":"Ann Oncol"},{"key":"2444_CR15","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39:4073\u2013126. https:\/\/doi.org\/10.1200\/JCO.21.01440.","journal-title":"J Clin Oncol"},{"key":"2444_CR16","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1056\/NEJMc2031717","volume":"384","author":"AS Thomas","year":"2021","unstructured":"Thomas AS, Ma W, Wang Y. Ustekinumab for refractory colitis associated with immune checkpoint inhibitors. N Engl J Med. 2021;384:581\u20133. https:\/\/doi.org\/10.1056\/NEJMc2031717.","journal-title":"N Engl J Med"},{"key":"2444_CR17","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1056\/NEJMc2002527","volume":"382","author":"K Esfahani","year":"2020","unstructured":"Esfahani K, Hudson M, Batist G. Tofacitinib for refractory immune-related colitis from PD-1 therapy. N Engl J Med. 2020;382:2374\u20135. https:\/\/doi.org\/10.1056\/NEJMc2002527.","journal-title":"N Engl J Med"},{"key":"2444_CR18","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s12328-025-02126-x","volume":"18","author":"S Igarashi","year":"2025","unstructured":"Igarashi S, Shimaya K, Fujimaki K, et al. Relapsed refractory immune checkpoint inhibitor-induced colitis treated with tacrolimus and maintained with vedolizumab. Clin J Gastroenterol. 2025;18:463\u20139. https:\/\/doi.org\/10.1007\/s12328-025-02126-x.","journal-title":"Clin J Gastroenterol"},{"key":"2444_CR19","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1158\/0008-5472.CAN-12-1337","volume":"72","author":"MWL Teng","year":"2012","unstructured":"Teng MWL, Vesely MD, Duret H, et al. Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state. In: Cancer Res. 2012;72:3987\u201396. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-1337.","journal-title":"Cancer Res"},{"key":"2444_CR20","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","volume":"388","author":"G D\u2019haens","year":"2023","unstructured":"D\u2019haens G, Dubinsky M, Kobayashi T, et al. Mirikizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2023;388:2444\u201355. https:\/\/doi.org\/10.1056\/NEJMoa2207940.","journal-title":"N Engl J Med"},{"key":"2444_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.800879","author":"L Tang","year":"2021","unstructured":"Tang L, Wang J, Lin N, et al. Immune checkpoint inhibitor-associated colitis: from mechanism to management. Front Immunol. 2021. https:\/\/doi.org\/10.3389\/fimmu.2021.800879.","journal-title":"Front Immunol"},{"key":"2444_CR22","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-018-0411-1","volume":"6","author":"H Abu-Sbeih","year":"2018","unstructured":"Abu-Sbeih H, Ali FS, Luo W, et al. Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. J Immunother Cancer. 2018;6:95. https:\/\/doi.org\/10.1186\/s40425-018-0411-1.","journal-title":"J Immunother Cancer"},{"key":"2444_CR23","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.cgh.2022.10.004","volume":"21","author":"A Shirwaikar Thomas","year":"2023","unstructured":"Shirwaikar Thomas A, Hanauer S, Wang Y. Immune checkpoint inhibitor enterocolitis vs idiopathic inflammatory bowel disease. Clin Gastroenterol Hepatol. 2023;21:878\u201390. https:\/\/doi.org\/10.1016\/j.cgh.2022.10.004.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2444_CR24","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.gie.2024.01.024","volume":"100","author":"Y Wang","year":"2024","unstructured":"Wang Y, Abu-Sbeih H, Tang T, et al. Novel endoscopic scoring system for immune mediated colitis: a multicenter retrospective study of 674 patients. Gastrointest Endosc. 2024;100:273\u2013e2824. https:\/\/doi.org\/10.1016\/j.gie.2024.01.024.","journal-title":"Gastrointest Endosc"},{"key":"2444_CR25","doi-asserted-by":"publisher","first-page":"e000451","DOI":"10.1136\/jitc-2019-000451","volume":"8","author":"MJ Mooradian","year":"2020","unstructured":"Mooradian MJ, Wang DY, Coromilas A, et al. Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis. J Immunother Cancer. 2020;8:e000451. https:\/\/doi.org\/10.1136\/jitc-2019-000451.","journal-title":"J Immunother Cancer"},{"key":"2444_CR26","doi-asserted-by":"publisher","first-page":"e011959","DOI":"10.1136\/jitc-2025-011959","volume":"13","author":"Z Tang","year":"2025","unstructured":"Tang Z, Shi J, Xu S, et al. Single-cell multiomics reveals macrophage-derived IL-23 and CXCL9\/10 drive pathogenic IFNG+IL17+\u2009T cells in immunotherapy-related colitis. J Immunother Cancer BMJ Publishing Group. 2025;13:e011959. https:\/\/doi.org\/10.1136\/jitc-2025-011959.","journal-title":"J Immunother Cancer BMJ Publishing Group"},{"key":"2444_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41798-2","author":"JW Lo","year":"2023","unstructured":"Lo JW, Cozzetto D, Alexander JL, et al. Immune checkpoint inhibitor-induced colitis is mediated by polyfunctional lymphocytes and is dependent on an IL23\/IFN\u03b3 axis. Nat Commun. 2023. https:\/\/doi.org\/10.1038\/s41467-023-41798-2.","journal-title":"Nat Commun"},{"issue":"9","key":"2444_CR28","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/s43018-024-00810-4","volume":"5","author":"F Dimitriou","year":"2024","unstructured":"Dimitriou F, Cheng PF, Saltari A, et al. A targetable type III immune response with increase of IL-17A expressing CD4+\u2009T cells is associated with immunotherapy-induced toxicity in melanoma. Nat Cancer. 2024;5(9):1390\u2013408. https:\/\/doi.org\/10.1038\/s43018-024-00810-4.","journal-title":"Nat Cancer"},{"issue":"Supplement 2","key":"2444_CR29","doi-asserted-by":"publisher","first-page":"ii3","DOI":"10.1093\/ecco-jcc\/jjac034","volume":"16","author":"GW Sewell","year":"2022","unstructured":"Sewell GW, Kaser A. Interleukin-23 in the pathogenesis of inflammatory bowel disease and implications for therapeutic intervention. J Crohns Colitis. 2022;16(Supplement 2):ii3\u201319. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjac034.","journal-title":"J Crohns Colitis"},{"key":"2444_CR30","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1136\/gutjnl-2017-315671","volume":"68","author":"H Schmitt","year":"2019","unstructured":"Schmitt H, Billmeier U, Dieterich W, et al. Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn\u2019s disease. Gut. 2019;68:814\u201328. https:\/\/doi.org\/10.1136\/gutjnl-2017-315671.","journal-title":"Gut"},{"key":"2444_CR31","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1016\/S0140-6736(24)01762-8","volume":"404","author":"M Ferrante","year":"2024","unstructured":"Ferrante M, D\u2019haens G, Jairath V, et al. Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn\u2019s disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study. Lancet. 2024;404:2423\u201336. https:\/\/doi.org\/10.1016\/S0140-6736(24)01762-8.","journal-title":"Lancet"},{"key":"2444_CR32","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1097\/DCR.0000000000003137","volume":"67","author":"TA Russell","year":"2024","unstructured":"Russell TA, Banerjee S, Lipman JM, et al. Tofacitinib is associated with increased risk of postoperative venous thromboembolism in patients with ulcerative colitis. Dis Colon Rectum. 2024;67:693\u20139. https:\/\/doi.org\/10.1097\/DCR.0000000000003137.","journal-title":"Dis Colon Rectum"},{"key":"2444_CR33","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/j.cgh.2018.11.035","volume":"17","author":"WJ Sandborn","year":"2019","unstructured":"Sandborn WJ, Pan\u00e9s J, D\u2019haens GR, et al. Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from global clinical trials. Clin Gastroenterol Hepatol. 2019;17:1541\u201350. https:\/\/doi.org\/10.1016\/j.cgh.2018.11.035.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2444_CR34","doi-asserted-by":"publisher","first-page":"e31465","DOI":"10.1371\/journal.pone.0031465","volume":"7","author":"K Tsuda","year":"2012","unstructured":"Tsuda K, Yamanaka K, Kitagawa H, et al. Calcineurin inhibitors suppress cytokine production from memory T cells and differentiation of na\u00efve T cells into cytokine-producing mature T cells. PLoS ONE. 2012;7:e31465. https:\/\/doi.org\/10.1371\/journal.pone.0031465.","journal-title":"PLoS ONE"},{"key":"2444_CR35","doi-asserted-by":"publisher","first-page":"e008232","DOI":"10.1136\/jitc-2023-008232","volume":"12","author":"C Harvey","year":"2024","unstructured":"Harvey C, Nahar KJ, McKeown J, et al. Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series. J Immunother Cancer. 2024;12:e008232. https:\/\/doi.org\/10.1136\/jitc-2023-008232.","journal-title":"J Immunother Cancer"},{"issue":"10","key":"2444_CR36","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1093\/ecco-jcc\/jjx081","volume":"11","author":"C Coutzac","year":"2017","unstructured":"Coutzac C, Adam J, Soularue E, et al. Colon immune-related adverse events: anti-CTLA-4 and anti-PD-1 blockade induce distinct immunopathological entities. J Crohns Colitis. 2017;11(10):1238\u201346. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjx081.","journal-title":"J Crohns Colitis"},{"issue":"2","key":"2444_CR37","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s10620-022-07598-2","volume":"68","author":"Y Takahashi","year":"2023","unstructured":"Takahashi Y, Nagaya T, Iwaya Y, et al. CD8+ lymphocyte infiltration is a specific feature of colitis induced by immune checkpoint inhibitors. Dig Dis Sci. 2023;68(2):451\u20139. https:\/\/doi.org\/10.1007\/s10620-022-07598-2.","journal-title":"Dig Dis Sci"},{"key":"2444_CR38","doi-asserted-by":"publisher","first-page":"e17729","DOI":"10.7759\/cureus.17729","volume":"13","author":"R Bhandari","year":"2021","unstructured":"Bhandari R, Ogeyingbo OD, Kareem R, et al. Efficacy and safety of vedolizumab in management of moderate to severe ulcerative colitis: a systematic review. Cureus. 2021;13:e17729. https:\/\/doi.org\/10.7759\/cureus.17729.","journal-title":"Cureus"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-026-02444-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-026-02444-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-026-02444-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T09:38:20Z","timestamp":1789378700000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-026-02444-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":38,"alternative-id":["2444"],"URL":"https:\/\/doi.org\/10.1007\/s12328-026-02444-8","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"assertion":[{"value":"4 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"<b>Conflict of interest<\/b>","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures were performed in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and the 1975 Declaration of Helsinki, as revised in 2013.","order":2,"name":"Ethics","label":"Human or animal rights","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from the patient.","order":3,"name":"Ethics","label":"<b>Informed consent<\/b>","group":{"name":"EthicsHeading","label":"Declarations"}}]}}